ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2294

The Role Of Patient Global Disease Activity Score In The Definition Of American College Of Rheumatology/European League Against Rheumatism Remission In Very Early Rheumatoid Arthritis  From The Norwegian Very Early Arthritis Clinic

Maria Dahl Mjaavatten1, Anne Julsrud Haugen2, Halvor Nygaard3, Olav Bjørneboe4, Patrik Stolt5, Cathrine Thunem6 and Tore Kristian Kvien1,7, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, 3Dept. of Rheumatology, Revmatismesykehuset Lillehammer, Lillehammer, Norway, 4Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, 5Dept. of Rheumatology, Innlandet Hospital Trust, Brumunddal, Norway, 6Dept. of Rheumatology, Betanien Hospital, Skien, Norway, 7Faculty of Medicine, University of Oslo, Oslo, Norway

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Early Rheumatoid Arthritis, patient outcomes and remission

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

In the ACR/EULAR criteria remission can be defined in two ways, either by fulfilment of 4 Boolean criteria or by a Simplified Disease Activity Index (SDAI) score ≤ 3.3. Failure to fulfill the patient global disease activity (PGA) score < 1 cm criterion in the Boolean version has been shown to be the major determinant of “near misses” of remission in established RA. It is not known if this factor is of the same importance when RA patients are identified and treated at a very early stage. The purpose of this study was to investigate the role of PGA in fulfilment of the ACR/EULAR remission criteria after 2 years in patients with RA in a very early arthritis clinic.

Methods:

Patients with arthritis of <16 weeks' duration were included in an early arthritis cohort from 2004-2010 and followed for 2 years with a comprehensive data collection. Patients were treated according to current clinical practice and not with a structured treat-to-target approach. Patients with RA according to the 2010 classification criteria with 2 years follow-up time were included in the present analysis. Frequency of 2-year remission was calculated according to both versions of the criteria, as well as which criterion was not fulfilled in patients fulfilling 3/4 Boolean criteria. 

Results:

Of 1086 very early arthritis patients included, 185 (17.0 %) had RA according to the 2010 criteria at inclusion and had 2-year data on Boolean remission (mean (SD) age 52.5 (13.8) years, n (%) females 112 (60.5), median (25-75 percentile) duration of symptoms at inclusion 63 (40-83)). 171 of these patients had data on SDAI remission. After 2 years, 41/185 (22.2 %) were in Boolean remission, while 65/171 (38.0 %) were in SDAI remission. 63 patients (34.5 %) fulfilled 3 of the Boolean criteria (criterion not fulfilled: PGA n=52, CRP n=5, TJC n=3, SJC n=1, missing data n=2). If the PGA cut-off was raised to ≤2, the remission rate increased to 61/185 (33.0 %). A PGA cut-off of ≤ 3 gave a remission rate of 72/185 (38.9 %). Omitting the PGA criterion, the remission rate was 93/185 (50.3 %).  Mean (range) PGA score in the 52 patients failing to fulfill the criteria due to elevated PGA was 3.5 (1.1-8.9). 44/52 (84.6 %) of patients with PGA > 1 had evaluator’s global disease activity (EGA) ≤ 1; 25 of these 44 (56.8 %) were in SDAI remission. 13 patients who were not in ACR/EULAR Boolean remission fulfilled the PGA criterion.

 

Conclusion:

In this very early arthritis clinic only 22% of early RA patients were in ACR/EULAR Boolean remission after 2 years of follow-up, while 38 % were in remission according to SDAI. Elevated PGA was the major reason for not being in remission in patients fulfilling 3/4 of the Boolean remission criteria, and in the majority of these patients EGA was ≤ 1. A PGA cut off of ≤ 3 resulted in a similiar remission rate (38.9 %) as with the index based (SDAI) remission definition. 


Disclosure:

M. D. Mjaavatten,
None;

A. J. Haugen,
None;

H. Nygaard,
None;

O. Bjørneboe,
None;

P. Stolt,
None;

C. Thunem,
None;

T. K. Kvien,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-patient-global-disease-activity-score-in-the-definition-of-american-college-of-rheumatologyeuropean-league-against-rheumatism-remission-in-very-early-rheumatoid-arthritis-from-the-n/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology